RxDoctor Payments Data

Shari Klinger, MD

Infectious Disease · Miami Beach, FLNPI 1700998333

Payments from drug & device makers

$7,396in general payments, 2019–2025

Across 355 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$2K
  • Johnson & Johnson$799
  • Theratechnologies Inc.$482
  • EMD Serono, Inc.$296
  • Merck$267
  • plus $527 from 10 others

What the payments were for

  • Food & beverage$7,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,396 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,221
Medicare patients
18
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala264$1,073,416
TivicayDolutegravir Sodium116$290,593
DovatoDolutegravir Sodium/Lamivudine74$228,609
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf44$211,491
CabenuvaCabotegravir/Rilpivirine21$132,701
PrezcobixDarunavir/Cobicistat52$131,035
OdefseyEmtricitab/Rilpiviri/Tenof Ala31$119,596
JulucaDolutegravir/Rilpivirine26$88,853
DescovyEmtricitabine/Tenofov Alafenam37$79,427
OzempicSemaglutide56$50,227
IsentressRaltegravir Potassium22$45,139
MytesiCrofelemer18$43,431
EliquisApixaban43$34,335
Darunavir25$31,553
JardianceEmpagliflozin16$17,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,723$1,152,843301 claims
Viiv Healthcare CompanyTivicay, Dovato, Cabenuva, Juluca$3,301$740,756237 claims
Johnson & JohnsonPrezcobix$799$131,03552 claims
Novo NordiskOzempic$17$50,22756 claims
MerckIsentress$267$45,13922 claims
Napo Pharmaceuticals IncMytesi$24$43,43118 claims
PfizerEliquis$127$34,33543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →